Cochrane

Protocol: To assess the efficacy and safety of methotrexate for psoriatic arthritis in adults.

Protocol: To assess the benefits (reduced incidence of vertebral, non-vertebral and hip fracture, improved quality of life) and harms (i.e. adverse effects) of pharmacological interventions for the prevention of bone density loss in critically ill patients.

Review Question We reviewed the evidence about the effect of multidisciplinary treatments on pain, disability, and work status among people who had been experiencing low back pain for six to 12 weeks. We defined multidisciplinary treatments as treatments that target physical as well as psychological or social aspects of low back pain and involve a ...

Review question We aimed to assess the benefits (improvement in pain, stiffness, physical function) and harms (gut and heart problems) of celecoxib compared with other similar drugs or a fake drug (placebo) for adults with rheumatoid arthritis. Background Rheumatoid arthritis is an auto-immune disease that causes the lining of joints to become inflamed ...

Bottom line There is moderate-quality evidence that oral gabapentin at doses of 1200 mg daily or more has an important effect on pain in some people with moderate or severe neuropathic pain after shingles or due to diabetes. Background Neuropathic pain comes from damaged nerves. It is different from pain messages that are carried along healthy nerves ...

Review question We evaluated benefits and harms of celecoxib, a drug used to treat people with osteoarthritis, to improve pain, movement, quality of life and drug safety. Background Osteoarthritis is a joint disease (mostly knees and hips) caused when cartilage wears away leading to pain, joint stiffness and inflammation, which can cause limited ...

Protocol: To assess the benefits and harms of oral strontium ranelate to treat osteoarthritis.

Protocol: To assess the benefits and harms of calcium and vitamin D supplementation singly or in combination for reducing fractures and increasing bone mineral density in healthy premenopausal women.

Review question We studied the benefits and harms of biologics or tofacitinib on people with rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX), in trials done until June 2015. Data was available for four TNF biologics (adalimumab, etanercept, golimumab, infliximab) and two non-TNF biologics (abatacept, rituximab). What ...

Protocol: To assess the benefits and harms of anti-sclerostin antibodies for the treatment of osteoporosis.